The Congressionally Directed Medical Research Programs (CDMRP) has pre-announced the FY26 Prostate Cancer Research Program, backed by Congressional appropriations as part of the $1.27 billion FY26 CDMRP allocation. This is the largest dedicated prostate cancer research funding program administered by the U.S. Department of Defense. It supports innovative, high-impact research with clinical relevance aimed at eliminating death and suffering from prostate cancer. Five distinct award mechanisms are anticipated, open to investigators at U.S. and international institutions.
Award Mechanisms & Eligibility:
- Data Science Award: Independent investigators at all levels; supports AI/ML, bioinformatics, computational biology, digital pathology, epidemiology, medical imaging applied to prostate cancer data
- Early Investigator Research Award: Early-career investigators; requires a mentor
- Idea Development Award — Established Investigator and New Investigator: High-risk/high-reward innovative prostate cancer research
- Physician Research Award: Early-career clinician investigators
All applications must address ≥1 overarching challenge: (1) Improve survivorship, (2) Develop/improve treatments for lethal prostate cancer, (3) Enhance clinical care, or (4) Define biology of progression to lethal disease.
Application Timeline:
- Pre-Announced: April 24, 2026 | Formal FOAs forthcoming on Grants.gov
- Full FOAs with specific deadlines will be posted on Grants.gov (CFDA 12.420) and eBRAP
- Pre-applications submitted via eBRAP; full applications via Grants.gov
Where to go for further information: